CCM
ENSC icon

Covington Capital Management’s Ensysce Biosciences ENSC Stock Holding History

Covington Capital Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 1207
2022
Q2 		– Hold
0
– – – 1108
2022
Q1 		– Hold
0
– – – 1115
2021
Q4 		– Sell
-1
Closed -$15K – 1019
2021
Q3 		$15K Buy
+1
New +$19.5K ﹤0.01% 752

Other funds holding ENSC

HVCM
HG Vora Capital Management New York $191M AUM 1.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MGIA
Moneta Group Investment Advisors St Louis, Missouri $13.3B AUM 18.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Covington Capital Management's ENSC Position: Q3 2022 in Review

Covington Capital Management held its Ensysce Biosciences (ENSC) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1207.

Covington Capital Management first reported a position in ENSC in Q3 2021 and has held it in 1 quarter since. The position peaked at $15K in Q3 2021. 16 funds tracked by Wall St. Rank hold ENSC as of Q3 2022.

  • Covington Capital Management held 0 shares of Ensysce Biosciences worth $0 as of Q3 2022.
  • Covington Capital Management left its Ensysce Biosciences share count unchanged in Q3 2022.
  • Ensysce Biosciences made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #1207 holding.
  • Covington Capital Management first reported a position in Ensysce Biosciences in Q3 2021 and has held it in 1 quarter since.
  • Covington Capital Management's Ensysce Biosciences position peaked at $15K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.